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Challenges and Strategies for 
Access to Treatment of Hepatitis C 
in Latin America
David Kershenobich and Nayelli Flores
Abstract
With the advent of all oral direct-acting antiviral drugs (DAAs) with a low 
incidence of side effects and very high success rates, we are entering an exciting 
new era in the treatment of hepatitis C virus (HCV), and now the major goal is the 
elimination of this viral infection. However, at least in Latin America, there are 
multiple barriers that must be attended.
Keywords: hepatitis C, direct-acting antiviral, treatment access, virus elimination, 
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1. Introduction
We are witnessing a new era in the treatment of HCV infection due to the 
development of DAAs that allows to cure a chronic disease without an effective 
vaccine. The therapy with pegylated interferon and ribavirin is no longer the 
standard of care. Unfortunately, there is a gap between these advances and the real 
access to treatment for patients in low- and middle-income countries (LMIC). In 
Latin America, the main identified barrier to access to hepatitis C treatment was 
for long a time the high price of these DAAs. While this issue has not yet been fully 
resolved, it has become evident that there are other gaps that need to be attended 
in order to undertake a comprehensive viral hepatitis elimination effort [1]. In this 
chapter, we propose to portray the main challenges that have not allowed fulfilling 
this purpose and present new strategies that could contribute toward addressing 
this health challenge.
2. Challenges to effectively treat HCV infection in Latin America
Chronic HCV infection is a health problem that affects more than 71 million 
people worldwide. HCV is associated with several hepatic pathologies, including 
cirrhosis and hepatocellular carcinoma as well as many other extrahepatic manifes-
tations that are a major cause of global health burden [2].
The real incidence of hepatitis C and cirrhosis in Latin America is unknown. 
It has been estimated that at least 10 million Latin Americans may be infected 
with HCV [3, 4]. In some Latin American countries that provided national data, 
cirrhosis death rates were between 5 and 17/100,000 for men and 3 and 5/100,000 
for women [5].
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Liver cirrhosis mortality trends vary widely among countries in Latin America. 
Mortality rates increased in Costa Rica, Guatemala, Honduras, and Paraguay, but 
fell in Chile, Mexico, and Argentina. In 1980, age-standardized cirrhosis mortality 
rates in Chile and Mexico were, respectively, 53.4 (43.6–67.9) per 100,000 and 45.9 
(35.6–57.0) per 100,000, the highest in the region. In 2010, Mexico remained the 
country with the highest cirrhosis mortality rate in the region, at 38.3 (30.7–47.5) 
per 100,000. Liver cirrhosis was the fourth leading cause of death in Mexico in 2010, 
accounting for 18% of deaths in males aged 40–49 years [6]. Disability, quality of life, 
and social aspects should be considered when assessing the impact of the disease.
2.1 Lack of epidemiological studies
Overall updated population-based epidemiological studies of viral hepatitis 
in most Latin American countries are still a significant challenge. This barrier is cru-
cial to define health policies in the region [7]. There is a paucity of epidemiological 
data from rural areas where a significant percentage of the population resides. Most 
data are focused on seroprevalence of the disease, and studies are typically cross-
sectional in design. Most of the studies have been conducted in select populations 
and do not allow to gain the real prevalence and incidence of HCV infection.
Efforts have been made to model the disease in some countries of the region, 
such as Mexico, Brazil, Argentina, and Chile. All of them indicate that if the num-
ber of patients identified and treated do not increase over the years, HCV-related 
morbidity and mortality are expected to increase, and the impact on the develop-
ment of liver cirrhosis and hepatocarcinoma may be overwhelming [8].
In Mexico, for example, with the majority of cases arising from transfusion prior 
to the implementation of blood screening protocol, the annual number of HCV 
infection was estimated to peak in the mid-1990s. The annual number of new cases 
was estimated at 5620 new cases in 2013 [9].
In 2013, the total number of viremic infections was estimated at 560,700 (326, 
900–605,200), and it was forecasted to decrease to 406,100 viremic infections in 
2030. The number of HCC cases in 2013 was estimated at 2660 cases, and it was fore-
casted to increase by 55% by 2030. The number of liver-related deaths will increase by 
55% from a base of 2370, while decompensated cirrhosis and compensated cirrhosis 
infections will increase 55 and 40% from a base of 6750 and 54,460 in 2013 [9].
In Argentina, there were an estimated 342,300 (155,000–537,000) infected 
individuals in 2013. Prevalence is estimated to have peaked at 382,700 patients in 
2002 and to decline to 237,000 by 2030. There will be 62,630 compensated cirrhotic 
patients in 2030 as compared to 37,110 in 2013. In addition, there will be 3510 cases 
of HCC, and 8470 patients will be progressing to decompensated cirrhosis by 2030. 
Liver-related deaths in 2030 will number 3060 as compared to 1550 deaths in 2013. 
In 2013, 13% of viremic cases are estimated to have compensated cirrhosis or more 
advanced liver disease (decompensated cirrhosis, HCC, or transplant), while this 
proportion will increase to 32% in 2030 [9].
This type of epidemiological pattern is most likely to occur in the different 
countries through Latin America unless diagnostic and treatment rates of the HCV 
infection are increased.
2.2 Inadequate awareness and screening
Worldwide, the number of people that are aware of the diagnosis of hepatitis C is 
low. One of the challenges with diagnosing HCV infection is that it is often asymp-
tomatic and that individuals seek medical attention only when they develop symp-
toms or signs of liver disease. In Mexico, for example, the average age at diagnosis 
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of hepatitis C is 60.7 years, and 44% of them have liver cirrhosis, indicating that 
patients are arriving late for diagnosis and treatment [10–12].
Screening for HCV infection is central for identifying unknown cases. The early 
diagnosis of HCV infection can help to reduce the burden of disease and limit trans-
mission to those at risk of infection or reinfection. Screening is critical to achieving 
the WHO targets by 2030 [13].
A high percentage of HCV-infected people lives in countries with limited 
resources to screen and treat hepatitis C. Latin America needs to overcome numer-
ous challenges such as the lack of awareness among health professionals and the 
public in general. Each country in the region needs to plan its public health policy 
and screening strategy, but overall linkage to care remains an important hurdle.
2.3 Political disinterest
Political interest around the issue of hepatitis C treatment is uneven in the Latin 
American region. While affordability of DAAs has improved significantly in some 
countries such as Brazil, Mexico, Colombia, and Argentina, through strategies 
such as facilitating and speeding up the registration of the new DAAs, negotiat-
ing prices, compulsory licensing or generic competition, and exploring financial 
means by governments, insurance companies, or patients remain a significant task 
to undertake [14].
Access to treatment in different countries of Latin America is not systematic 
as they organize their healthcare in diverse ways so that eligibility and availability 
criteria vary significantly. Furthermore, specific guidance about health care entitle-
ment is either not available, unclear, or not followed by medical professionals 
involved in diagnosing and treating hepatitis C.
2.4 Insufficient health care providers
Another important barrier restricting access to treatment in Latin America, 
particularly for the inhabitants with the lowest resources, is the limitations of 
providers of care. As a result, the number of patients referred for subspecialist 
evaluation remains low, and even when it occurs, patients may face long-distance 
travel, extended waiting time, and a lack of scheduling flexibility [15].
Among primary care provider’s risk factors for HCV infection are not regularly 
sought, and deficiencies in HCV testing represent an additional barrier. Knowledge 
of HCV is generally inadequate.
Limited liver specialist availability through the region further contributes to the 
restriction of widespread opportunity of receiving treatment.
2.5 Identification of new risk factors
Risk factors for hepatitis C have changed over the years. A lack of knowledge 
regarding risk factors and treatment may contribute to low cure rates [16]. As 
blood bank screening has become almost universal, prevention and control of HCV 
should focus on recognizing high-risk population. In addition, rural populations, 
especially in areas with lower economic provision, should be under more attention. 
Evidence reported that intravenous or intranasal drug use and incarceration as well 
as the presence of hepatitis C in special populations such as patients with chronic 
renal failure in pre-dialysis, those in hemodialysis or co-infected individuals with 
HIV/hepatitis B are independent indicators of risk for past or present HCV infection 
[17]. The evolution of these risk factors will provide insights into understanding the 
future burden of hepatitis C.
Hepatitis B and C
4
Another important issue is the recognition that people remain at risk of reinfec-
tion with hepatitis C virus (HCV), even after clearance of the primary infection [18]. 
A significant issue is the recognition of cofactors that can accelerate progression of 
hepatic fibrosis in patients with HCV, such as obesity, diabetes mellitus, co-infection 
with HIV or hepatitis B, and alcohol consumption [19].
In order to achieve the continuum of care, identification of challenges in the 
region becomes very important. Special attention must be given at individual 
countries as their challenges may differ in their impact and significance (Figure 1).
3. Strategies for accessing HCV infection treatment
3.1  Conducting national campaigns of information and detection of  
hepatitis C in the general population
A social communication strategy is required to increase the perception that 
hepatitis C is a preventable and curable disease. It is necessary to educate the 
population about the risk factors and easy access to screening, utilizing massive 
ways of communication such as newspaper, magazine, book publishing, as well as 
radio, television, internet, film, and social media. It is important to make sure that 
messages are backed up by data in order to avoid confusion and being visionary to 
provide a good reason to attend the message. The inclusion of the rapid test should 
be recommended as part of routine test in medical examinations of high-risk indi-
viduals. This test allows point-of-care testing that can take place outside the clinical 
laboratory and can be administered and interpreted by nonspecialists, the results 
are available in 5–10 min, and its sensibility is 95–99% and specificity 99–100% 
[20]. In those cases with a positive test, it is necessary to determine a viral load to 
detect viremic cases and guarantee access to treatment.
3.2 Training programs for medical and nursing staff
It is recommendable to expand the number of health care professionals who can 
diagnose and administer DAAs, especially in rural areas fostering engagement in the 
continuum of care. Primary care physicians are in an ideal position to offer screen-
ing and diagnosis. Patients with advanced liver disease or complicated cases should 
be referred to the gastroenterologist, infectious disease specialist, or hepatologist. 
Nurses are at the forefront of providing information about the spread and diagnosis 
and treatment options available [21].
Figure 1. 
Challenges to effectively treat HCV infection in Latin America.
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To pursue this goal, we propose to connect health teams from remote areas with 
specialists in medical centers in order to promote the continuity of patient care.
The training course includes:
• Epidemiology of HCV infection.
• Transmission of HCV infection.
• Detection of HCV infection in risk groups.
• Treatment of HCV infection.
• Strategies for the prevention of hepatitis C.
The Extension for Community Healthcare Outcomes (ECHO) model by the 
University of New Mexico Health Sciences Center (UNMHSC) has developed a 
platform to deliver complex specialty medical care to underserved populations 
through an innovative educational model of team-based interdisciplinary develop-
ment. Using state-of-the-art telehealth technology, best practice protocols, and 
case-based learning, ECHO trains and supports primary care providers to develop 
knowledge and self-efficacy in hepatitis. ECHO has signed agreements in some 
Latin American countries which will contribute to advance the continuum of care 
for hepatitis C [22].
These types of programs will increase the familiarization of hepatitis C among 
general practitioners and nurses. They can be implemented taking advantage of the 
structure of the available health subsystems in every Latin American country.
3.3 Implementation of central laboratories to perform diagnostic tests
Rural communities face barriers when accessing health services, including facili-
ties to perform laboratory studies. Latin America is confirmed by a diverse group 
of countries with great urban and rural disparities. Their health systems are usually 
structured in three levels: national, state, and local or their equivalents for every 
nation. Since 1990 every country in the region has gone through a series of health 
sector reforms with the aim of increasing equity, effectiveness, and coverage of 
health systems; unfortunately, despite their positive results, they have not achieved 
the proposed goals.
An important strategy would be the implementation of point-of-care testing in 
rural areas and instrument the structure to send blood samples to central laborato-
ries when necessary. One of the primary goals of central laboratories is to achieve a 
48-hour or less turnaround on the shipment of laboratory specimens from labora-
tory sites to the central lab location. These laboratories must have minimum levels 
of infrastructure, human resources, and quality standards to guarantee technical 
competence in the analytical framework. At the local level, this reference network 
could be established at health centers, hospitals, or other places defined by the state, 
with operational scope within a geographical area.
3.4  Regional programs to integrate medical specialists and health care  
providers from the prisons and addiction centers
Among these populations prevalence of hepatitis C is markedly increased 
and has been documented between 4 and 96% in several studies [23]. They 
are by far undiagnosed and unlinked to care. Very seldom do they seek medi-
cal attention unless they present overt clinical liver disease. As a preventive 
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Figure 2. 
Strategies for accessing HCV infection treatment.
strategy, these patients should be screened actively, diagnosed, and be treated 
with DAAs. Treatment programs should include opiate substitution treatment 
and various harm reduction programs, including needle exchange programs. 
Ideally, these services should be delivered in the same place with an integrated 
approach [24, 25].
In the annual budgets of the prisons, it is necessary to foresee human and 
material resources to ensure they have medical facilities that improve HCV screen-
ing by point-of-care testing, outreach methods with mobile teams, rapid tests, and 
FibroScan to allow them to offer access to DAAs. We must strengthen the system of 
general prevention of hepatitis among all inmates as well.
3.5 Providing care in hospitals with focus on high-risk populations
A micro-elimination strategy should be implemented at individual hospitals, 
screening, diagnosing, and treating high-risk population attending for medical care. 
These populations include patients with liver diseases, patients with chronic renal 
failure, patients in pre-dialysis, patients with solid organ transplants, hemophiliacs, 
diabetics, and immunosuppressed patients from different etiologies as well as those 
pursuing emergency care. The micro-elimination strategy at these places should 
include the medical and paramedical personnel.
At the level of hospitals and health centers, an anonymous record of informa-
tion on patients with hepatitis C should be implemented. This registry will provide 
epidemiological information on the route of acquisition of the disease, comorbidi-
ties and barriers to treatment access and document the response to DAAs and serve 
as an instrument that permits recording follow-up.
3.6 Simplification of bureaucratic procedures
Often in Latin American countries, access to DAAs is mired in bureaucracy 
implying excessive requirements difficult to meet for both patient and doctors. It is 
necessary to speed up the process in order to reduce the long queue of medication 
assignment, awaiting approval response, and shorten the long queue of medications 
awaiting review. At the institutional level, the form of payment (refund) of the 
medication can take months or years, so this is another important issue to overcome 
in order to make DAAs easily accessible.
Higher rates of DAA treatment must be accompanied by efficient screening, 
increased awareness, and more prescribers. It is necessary to innovate in the screen-
ing process, uncovering previously unidentified cases and those in the greatest need 
of treatment or at a high risk of transmitting the infection.
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Understanding the care cascade is vital for eliminating the virus. Reducing the 
HCV burden requires educational effort and scale-up of DAA therapies. The simplic-
ity of oral regimens that are effective across HCV genotypes expands the number of 
physicians that can prescribe DAAs with scalable treatment models. Novel prescrip-
tion systems are being developed, whereby internists and general practitioners may 
be eligible to prescribe DAAs in consultation with specialists (Figure 2).
4. Conclusions
Hepatitis C in Latin America has now become an important health issue. 
Strategies to identify patients have changed over time, shifting from blood bank to 
occult patients in high-risk populations (Figure 3). Implementation of treatment 
access is the main objective in order to achieve the WHO strategy of elimination 
by 2030. The pathway toward this goal is flagged by several barriers, including 
simplified detection, drug costs, public and professional education, awareness, and 
government concern, so the majority of HCV-infected individuals can benefit from 
the new generation of HCV antivirals.
Strategies to eliminate HCV infection must emphasize that this is a curable and 
preventable disease. As therapeutic regimens have become simpler and almost without 
side effects, the number of health care professionals who can diagnose and administer 
hepatitis C treatment is expanding the number of patients accessing treatment.
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Figure 3. 
Hepatitis C a Global Health issue.
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